Public Company News

BIG TREE CLOUD ANNOUNCED RESIGNATION AND APPOINTMENT OF DIRECTORS

SHENZHEN, China, Oct. 31, 2024 /PRNewswire/ -- Big Tree Cloud Holdings Limited ("Big Tree Cloud" or the "Company") (NASDAQ: DSY) (NASDAQ: DSYWW), a company devoted to the development, production, and sales of personal care products and other consumer goods inChina, today announced  the following ...

2024-11-01 04:00 3255

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") inPortugal, for exclusive rights to the commercialization of clobetasol propionate oph...

2024-10-31 21:36 4038

Caravelle International Group Announces Interim Unaudited Financial Results for Period Ended April 30, 2024

HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Caravelle International Group (Nasdaq: HTCO), a global ocean technology company, today announced its Condensed Interim Unaudited financial results for the period endedApril 30, 2024. During the reported period, Caravelle achieved revenue of approximately...

2024-10-31 21:15 3527

"Pinkfong & Hogi Mini Movie: The Tricky Three Cars" to Premiere Globally on Netflix

-  Pinkfong's hit series "Pinkfong Wonderstar" expands with its first spin-off special focusing on Hogi -  The mini-movie is set to captivate audiences worldwide exclusively on Netflix onNovember 3 Click HERE for Trailer and HERE

2024-10-31 21:05 4404

The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024

WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...

2024-10-31 21:00 2279

iQIYI's 'Love On Theater' Premieres 'Fangs of Fortune,' Setting Benchmark for C-Drama Virtual Production

BEIJING, Oct. 31, 2024 /PRNewswire/ -- iQIYI, China's leading online entertainment platform, premieredFangs of Fortune in late October, the latest release under 'Love On Theater.' Inspired byThe Classic of the Mountains and Seas, an ancient Chinese mythological text, this fantasy period drama unf...

2024-10-31 20:15 3555

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...

2024-10-31 20:14 2377

NaaS Technology CFO to Headline UBS Charging Industry Call Series

BEIJING, Oct. 31, 2024 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that Mr. Steven Sim, Chief Financial Officer of NaaS, will be featured on UBS's Charging Industry Call Series onNovember...

2024-10-31 20:00 2416

Cango Inc. to Report Third Quarter 2024 Financial Results on November 4, 2024 Eastern Time

SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading automotive transaction service platform in China, today announced that it plans to release its third quarter 2024 financial results after the market closes on Monday, November 4, 2024. The earnin...

2024-10-31 20:00 3132

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...

2024-10-31 20:00 2040

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...

2024-10-31 19:00 2882

Recurrent Energy to deliver 1,800 MWh of energy storage and 150 MWac of solar capacity to Arizona Public Service by 2026

Recurrent Energy's latest energy storage and solar tolling agreements with APS supportArizona's expanding energy needs GUELPH, ON and PHOENIX, Oct. 31, 2024 /PRNewswire/ -- Recurrent Energy , a subsidiary of Canadian Solar Inc. ("Canadian Solar") (NASDAQ: CSIQ) and ...

2024-10-31 19:00 2255

Recurrent Energy Announces Successful Operation of 134 MW Solar Project

Autodesk, Inc., Biogen Inc., EMD Electronics and Wayfair Inc. are now purchasing renewable energy from theTexas project HOUSTON and GUELPH, ON, Oct. 31, 2024 /PRNewswire/ -- Recurrent Energy , a subsidiary of Canadian Solar Inc . ("Can...

2024-10-31 19:00 3348

China Yuchai Terminates Its Share Buyback Plan

SINGAPORE, Oct. 31, 2024 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD)("China Yuchai" or the "Company") today announced that its Board of Directors has approved to terminate its share buyback plan with immediate effect.  The share buyback plan was adopted on June 7, 2024, under ...

2024-10-31 18:00 3831

NetEase to Report Third Quarter 2024 Financial Results on November 14

HANGZHOU, China, Oct. 31, 2024 /PRNewswire/ -- NetEase, Inc. (NASDAQ: NTES and HKEX: 9999, "NetEase" or the "Company"), a leading internet and game services provider, today announced that it will report financial results for the 2024 third quarter onThursday, November 14, 2024, before the open of...

2024-10-31 16:30 2704

Youdao to Report Third Quarter 2024 Financial Results on November 14

HANGZHOU, China, Oct. 31, 2024 /PRNewswire/ -- Youdao, Inc. ("Youdao" or the "Company") (NYSE: DAO), an intelligent learning company with industry-leading technology inChina, today announced that it will report its third quarter 2024 financial results onThursday, November 14, 2024, before the ope...

2024-10-31 16:30 2175

Full Truck Alliance Co. Ltd. to Announce Third Quarter 2024 Financial Results on Wednesday, November 20, 2024

Earnings Call Scheduled for 7:00 A.M. U.S. ET on November 20, 2024  GUIYANG, China, Oct. 31, 2024 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM), a leading digital freight platform, today announced that it will release its third quarter 2024 unaudited financial ...

2024-10-31 16:00 2438

"Bleach: Brave Souls" Anime Broadcast Celebration Special: Thousand-Year Blood War Zenith Summons: Puppets Begins with Thousand-Year Blood War 2024 Versions of Giselle & Others

TOKYO, Oct. 31, 2024 /PRNewswire/ -- KLab Inc., a leader in online mobile games, announced that its hit 3D action gameBleach: Brave Souls will be holding the Anime Broadcast Celebration Special: Thousand-Year Blood War Zenith Summons: Puppets to celebrate the broadcasting of the animated TV serie...

2024-10-31 15:40 2985

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...

2024-10-31 14:31 2143

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:02 2534
1 ... 213214215216217218219 ... 768